Mark K. Wedel - Concepedia

Author

Mark K. Wedel

Also Known As

M K Wedel, M Wedel, M. K. WEDEL, M. WEDEL, M. WEDEL *, M. Wedel, M.K. Wedel, Mark K Wedel, Mark K. Wedel, Mark Karl Wedel

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Ionis Pharmaceuticals (United States)Access to Nutrition Foundation University of Oklahoma Oklahoma Foundation for Digestive Research Amsterdam UMC Location University of Amsterdam

About

Mark K. Wedel is an author at Ionis Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	695
2	Health Sciences	2	2	114
3	Engineering	1	1	19
4	Natural Sciences	1	1	48
5	Biochemistry	1	1	48

Mark K. Wedel

Publications

Citations

H-Index

Page 1

	Year	Citations
Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B John J.P. Kastelein, Mark K. Wedel, Brenda F. Baker, Circulation	2006	356
Partial Liquid Ventilation in Adult Patients with Acute Respiratory Distress Syndrome Robert M. Kacmarek, Herbert Wiedemann, Philip T. Lavin, American Journal of Respiratory and Critical Care Medicine	2005	163
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy Fatima Akdim, Erik S.G. Stroes, Eric J.G. Sijbrands, Journal of the American College of Cardiology Antisense InhibitorOxysterolCardiovascular DiseaseMedicineHyperlipidemia	2010	160
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule‐1, in the treatment of chronic, unremitting pouchitis Philip B. Miner, Mark K. Wedel, Barbara L. Bane, Alimentary Pharmacology & Therapeutics	2004	137
A Phase II dose ranging, double‐blind, placebo‐controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left‐sided ulcerative colitis Sander J. H. van Deventer, Mark K. Wedel, Brenda F. Baker, Alimentary Pharmacology & Therapeutics	2006	126
A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn’s Disease Bruce Yacyshyn, William Y. Chey, Mark K. Wedel, Clinical Gastroenterology and Hepatology InflammationAnti-inflammatoryAntisense InhibitorMucosal ImmunologyGastrointestinal Pharmacology	2007	124
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia Fatima Akdim, Diane L. Tribble, JoAnn Flaim, European Heart Journal	2011	123
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100 Rosie Z. Yu, Kristina M. Lemonidis, Mark J. Graham, Biochemical Pharmacology Cross-species ComparisonMedicineApolipoprotein B-100PharmacologyImmunology	2008	119
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left‐sided ulcerative colitis: a randomized, double‐blind, active‐controlled trial Philip B. Miner, Mark K. Wedel, S. Xia, Alimentary Pharmacology & Therapeutics	2006	104
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe Rosie Z. Yu, Richard S. Geary, JoAnn D Flaim, Clinical Pharmacokinetics Mipomersen SodiumMolecular PharmacologyMedicinePharmacokinetic InteractionPharmacotherapy	2008	101

Page 1